FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285098637> ?p ?o ?g. }

• W4285098637 endingPage "100201" @default.
• W4285098637 startingPage "100201" @default.
• W4285098637 abstract "PurposeTo investigate the natural course of pachychoroid pigment epitheliopathy (PPE).DesignA retrospective cohort study.SubjectsFrom the Kyoto central serous chorioretinopathy (CSC) cohort consisting of 548 patients with CSC as of September 2020, we included consecutive unilateral patients with acute or chronic CSC between January 2013 and December 2016.MethodsAll patients underwent complete ophthalmic examination, including multimodal imaging such as fundus autofluorescence, spectral-domain optical coherence tomography, and fluorescein angiography/indocyanine green angiography and/or optimal coherence tomography angiography. The fellow eyes of eyes diagnosed with CSC were screened for PPE, and their natural course was evaluated. We also evaluated the association of ARMS2 rs10490924, CFH rs800292, TNFRSF10A rs13278062, and GATA5 rs6061548 genotypes with the natural course.Main Outcome MeasuresIncidence of CSC, pachychoroid neovasculopathy, and pachychoroid geographic atrophy (GA).ResultsIn total, 165 patients with unilateral CSC (mean age, 55.7 ± 12.6 years; female, 22.4%) were included from the Kyoto CSC cohort. Among them, 148 (89.7%) were diagnosed as having PPE in their non-CSC eye. Survival analysis revealed that 16.8% of PPE eyes developed CSC during the 6-year follow up, whereas non-PPE eyes did not. Although genetic factors did not have significant association with CSC development (P > 0.05, log-rank test), choroidal vascular hyperpermeability (CVH) and subfoveal choroidal thickness (SFCT) were significantly associated with CSC incidence (P = 0.001, log-rank test). Survival analysis showed that eyes without CVH and eyes with SFCT < 300 μm did not develop CSC during the 6-year follow-up. Pachychoroid neovasculopathy developed in only 1 eye with PPE during a follow-up of 46.4 months. Pachychoroid GA did not develop in any of the studied eyes.ConclusionsThis study revealed a natural history of PPE in a relatively large Japanese cohort. Choroidal vascular hyperpermeability and SFCT were significant risk factors for the development of CSC in PPE eyes. Although the current results cannot be generalized for all eyes with PPE, these findings present an important clinical implication. To investigate the natural course of pachychoroid pigment epitheliopathy (PPE). A retrospective cohort study. From the Kyoto central serous chorioretinopathy (CSC) cohort consisting of 548 patients with CSC as of September 2020, we included consecutive unilateral patients with acute or chronic CSC between January 2013 and December 2016. All patients underwent complete ophthalmic examination, including multimodal imaging such as fundus autofluorescence, spectral-domain optical coherence tomography, and fluorescein angiography/indocyanine green angiography and/or optimal coherence tomography angiography. The fellow eyes of eyes diagnosed with CSC were screened for PPE, and their natural course was evaluated. We also evaluated the association of ARMS2 rs10490924, CFH rs800292, TNFRSF10A rs13278062, and GATA5 rs6061548 genotypes with the natural course. Incidence of CSC, pachychoroid neovasculopathy, and pachychoroid geographic atrophy (GA). In total, 165 patients with unilateral CSC (mean age, 55.7 ± 12.6 years; female, 22.4%) were included from the Kyoto CSC cohort. Among them, 148 (89.7%) were diagnosed as having PPE in their non-CSC eye. Survival analysis revealed that 16.8% of PPE eyes developed CSC during the 6-year follow up, whereas non-PPE eyes did not. Although genetic factors did not have significant association with CSC development (P > 0.05, log-rank test), choroidal vascular hyperpermeability (CVH) and subfoveal choroidal thickness (SFCT) were significantly associated with CSC incidence (P = 0.001, log-rank test). Survival analysis showed that eyes without CVH and eyes with SFCT < 300 μm did not develop CSC during the 6-year follow-up. Pachychoroid neovasculopathy developed in only 1 eye with PPE during a follow-up of 46.4 months. Pachychoroid GA did not develop in any of the studied eyes. This study revealed a natural history of PPE in a relatively large Japanese cohort. Choroidal vascular hyperpermeability and SFCT were significant risk factors for the development of CSC in PPE eyes. Although the current results cannot be generalized for all eyes with PPE, these findings present an important clinical implication." @default.
• W4285098637 created "2022-07-14" @default.
• W4285098637 creator A5021225431 @default.
• W4285098637 creator A5027455858 @default.
• W4285098637 creator A5032878321 @default.
• W4285098637 creator A5033383514 @default.
• W4285098637 creator A5035233738 @default.
• W4285098637 creator A5049463882 @default.
• W4285098637 creator A5053130083 @default.
• W4285098637 creator A5064807449 @default.
• W4285098637 creator A5066340137 @default.
• W4285098637 creator A5079543730 @default.
• W4285098637 creator A5086219366 @default.
• W4285098637 creator A5090129110 @default.
• W4285098637 date "2022-12-01" @default.
• W4285098637 modified "2023-09-30" @default.
• W4285098637 title "Natural Course of Pachychoroid Pigment Epitheliopathy" @default.
• W4285098637 cites W1586003775 @default.
• W4285098637 cites W1977261713 @default.
• W4285098637 cites W2011326884 @default.
• W4285098637 cites W2025287737 @default.
• W4285098637 cites W2046942052 @default.
• W4285098637 cites W2065639445 @default.
• W4285098637 cites W2106432510 @default.
• W4285098637 cites W2233221674 @default.
• W4285098637 cites W2320782142 @default.
• W4285098637 cites W2323092704 @default.
• W4285098637 cites W2408303061 @default.
• W4285098637 cites W2580476816 @default.
• W4285098637 cites W2613038931 @default.
• W4285098637 cites W2743902174 @default.
• W4285098637 cites W2748308110 @default.
• W4285098637 cites W2770505124 @default.
• W4285098637 cites W2805485714 @default.
• W4285098637 cites W2868988997 @default.
• W4285098637 cites W2886521964 @default.
• W4285098637 cites W2891988471 @default.
• W4285098637 cites W2947319954 @default.
• W4285098637 cites W2964158106 @default.
• W4285098637 cites W2996373294 @default.
• W4285098637 cites W3016847035 @default.
• W4285098637 cites W3037922100 @default.
• W4285098637 cites W3095879154 @default.
• W4285098637 cites W3099337981 @default.
• W4285098637 cites W3111673928 @default.
• W4285098637 cites W3164822084 @default.
• W4285098637 cites W3172189454 @default.
• W4285098637 cites W3177582547 @default.
• W4285098637 cites W4225305737 @default.
• W4285098637 cites W4226258812 @default.
• W4285098637 cites W4232841428 @default.
• W4285098637 cites W860837004 @default.
• W4285098637 doi "https://doi.org/10.1016/j.xops.2022.100201" @default.
• W4285098637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36531587" @default.
• W4285098637 hasPublicationYear "2022" @default.
• W4285098637 type Work @default.
• W4285098637 citedByCount "1" @default.
• W4285098637 countsByYear W42850986372023 @default.
• W4285098637 crossrefType "journal-article" @default.
• W4285098637 hasAuthorship W4285098637A5021225431 @default.
• W4285098637 hasAuthorship W4285098637A5027455858 @default.
• W4285098637 hasAuthorship W4285098637A5032878321 @default.
• W4285098637 hasAuthorship W4285098637A5033383514 @default.
• W4285098637 hasAuthorship W4285098637A5035233738 @default.
• W4285098637 hasAuthorship W4285098637A5049463882 @default.
• W4285098637 hasAuthorship W4285098637A5053130083 @default.
• W4285098637 hasAuthorship W4285098637A5064807449 @default.
• W4285098637 hasAuthorship W4285098637A5066340137 @default.
• W4285098637 hasAuthorship W4285098637A5079543730 @default.
• W4285098637 hasAuthorship W4285098637A5086219366 @default.
• W4285098637 hasAuthorship W4285098637A5090129110 @default.
• W4285098637 hasBestOaLocation W42850986371 @default.
• W4285098637 hasConcept C118487528 @default.
• W4285098637 hasConcept C142724271 @default.
• W4285098637 hasConcept C150173356 @default.
• W4285098637 hasConcept C167135981 @default.
• W4285098637 hasConcept C2776391266 @default.
• W4285098637 hasConcept C2778257484 @default.
• W4285098637 hasConcept C2780248432 @default.
• W4285098637 hasConcept C71924100 @default.
• W4285098637 hasConcept C72563966 @default.
• W4285098637 hasConceptScore W4285098637C118487528 @default.
• W4285098637 hasConceptScore W4285098637C142724271 @default.
• W4285098637 hasConceptScore W4285098637C150173356 @default.
• W4285098637 hasConceptScore W4285098637C167135981 @default.
• W4285098637 hasConceptScore W4285098637C2776391266 @default.
• W4285098637 hasConceptScore W4285098637C2778257484 @default.
• W4285098637 hasConceptScore W4285098637C2780248432 @default.
• W4285098637 hasConceptScore W4285098637C71924100 @default.
• W4285098637 hasConceptScore W4285098637C72563966 @default.
• W4285098637 hasIssue "4" @default.
• W4285098637 hasLocation W42850986371 @default.
• W4285098637 hasLocation W42850986372 @default.
• W4285098637 hasLocation W42850986373 @default.
• W4285098637 hasLocation W42850986374 @default.
• W4285098637 hasOpenAccess W4285098637 @default.
• W4285098637 hasPrimaryLocation W42850986371 @default.
• W4285098637 hasRelatedWork W2088929624 @default.

• next